Jacob Asset Management Of New York LLC Arbutus Biopharma Corp Transaction History

Jacob Asset Management Of New York LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.91 - $2.85 $62,266 - $92,910	-32,600 Reduced 14.82%	187,400 $436,000
Q2 2022 Aug 11, 2022	BUY	$1.98 - $3.17 $39,600 - $63,400	20,000 Added 10.0%	220,000 $596,000
Q1 2022 May 12, 2022	SELL	$2.42 - $3.98 $169,400 - $278,600	-70,000 Reduced 25.93%	200,000 $596,000
Q4 2021 Feb 09, 2022	SELL	$3.11 - $4.61 $217,700 - $322,700	-70,000 Reduced 20.59%	270,000 $1.05 Million
Q2 2021 Oct 04, 2021	BUY	$2.5 - $3.51 $200,000 - $280,800	80,000 Added 30.77%	340,000 $1.03 Million

Q1 2021 Oct 04, 2021	BUY	$3.14 - $4.84 $816,400 - $1.26 Million	260,000 New	260,000 $866,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $489M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.